Description:
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced or metastatic solid tumors with a BRCA or ATM defect.
Title
- Brief Title: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
- Official Title: A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
Clinical Trial IDs
- ORG STUDY ID:
B9991032
- SECONDARY ID:
2018-000345-39
- NCT ID:
NCT03565991
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Genes, BRCA 1
Interventions
Drug | Synonyms | Arms |
---|
Avelumab | Bavencio | Combination of avelumab and talazoparib |
Talazoparib | MDV3800, BMN 673 | Combination of avelumab and talazoparib |
Purpose
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced or metastatic solid tumors with a BRCA or ATM defect.
Detailed Description
Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against
programmed death ligand 1 (PD-L1). Avelumab selectively binds to PD-L1 and competitively
blocks its interaction with programmed death receptor 1 (PD-1), thereby interfering with this
key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single
agent and in combination with other anti cancer therapies in patients with locally advanced
or metastatic solid tumors and various hematological malignancies.
Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate [ADP] ribose)
polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene
mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as
synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair,
replication, and transcription.
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced (primary or recurrent) or metastatic solid tumors with a BReast CAncer
susceptibility gene (BRCA)1, or BRCA2, or ataxia telangiectasia mutated (ATM) gene defect.
Trial Arms
Name | Type | Description | Interventions |
---|
Combination of avelumab and talazoparib | Experimental | Single arm open label | |
Eligibility Criteria
Inclusion Criteria:
- BRCA1, BRCA2 and/or ATM gene defect.
- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
tumors that are not amenable for treatment with curative intent
- Availability a tumor tissue sample from a diagnostic biopsy/surgery or a metastatic
tumor biopsy.
- Progressive disease at study enrollment.
- Minimum age 18 years (in Japan, minimum age 20 years).
- ECOG performance status 0 or 1.
- Adequate bone marrow, renal and liver function.
- For childbearing female patients, negative serum or urine pregnancy test at screening
- Signed and dated informed consent document.
Exclusion Criteria:
- Prior anti-cancer therapy or radiation therapy within 2 weeks prior to enrolment.
Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been
completed at least 2 days prior to enrolment and no significant toxicity are expected.
- Major surgery within 4 weeks prior to study enrollment.
- Current use of immunosuppressive medication at the time of study enrollment.
- Known prior severe hypersensitivity to investigational products or any component in
their formulations
- Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis,
pulmonary fibrosis.
- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.
- Prior organ transplantation including allogenic stem-cell transplantation.
- Administration of live attenuated vaccines within 4 weeks of study enrollment.
- Diagnosis of myelodysplastic syndrome.
- Known symptomatic brain metastases requiring steroids.
- Persisting toxicity related to prior therapy Grade >1.
- Known history of HIV or AIDS.
- Positive HBV or HCV test indicating acute or chronic infection.
- Active infection requiring systemic therapy.
- Clinically significant (active) cardiovascular disease: cerebral vascular
accident/stroke or myocardial infarction within 6 months prior to study enrollment;
unstable angina, congestive heart failure or a serious cardiac arrhythmia requiring
medication.
- Diagnosis of any other malignancy within 2 years prior to study enrollment, except for
adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of
the breast, bladder, or cervix, or low-grade prostate cancer or other early-stage
low-risk cancers.
- Pregnant or breastfeeding female patients; female or male patients who are able to
have children who are unable or unwilling to use contraception as outlined in the
protocol.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Confirmed Objective Response (OR) |
Time Frame: | From date of first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to approximately 24 months |
Safety Issue: | |
Description: | Confirmed OR in patients with locally advanced or metastatic solid tumors with BRCA 1/2 or ATM defect, as assessed by Blinded Independent Central Review using RECIST v1.1 and, in patients with mCRPC, RECIST v1.1. and PCWG3. |
Secondary Outcome Measures
Measure: | Confirmed OR as assessed by the investigator |
Time Frame: | From the first dose of study treatment until the date of first documented disease progression or date of death from any cause, whichever comes first, assessed up to approximately 24 months |
Safety Issue: | |
Description: | Confirmed OR as assessed by the investigator, using RECIST v1.1 and, in patients with mCRPC, RECIST v1.1 and PCWG3. |
Measure: | Time to tumor response (TTR) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | TTR is defined for patients with confirmed objective response (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response. |
Measure: | Duration of response (DR) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | DR is defined for patients with confirmed objective response (CR or PR) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. |
Measure: | Progression free survival (PFS) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | PFS is defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first. |
Measure: | Overall survival (OS) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | OS is defined as the time from the first dose of study treatment to the date of death. |
Measure: | Time to prostate-specific antigen (PSA) progression for mCRPC patients |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | Time to PSA progression is defined as the time from the first dose to the date that a greater than or equal to 25% increase in PSA from baseline. |
Measure: | CA-125 response for ovarian cancer patients |
Time Frame: | Baseline and Day 1 of each Cycle (1 cycle is 28 days) |
Safety Issue: | |
Description: | CA-125 response is defined as at least a 50% reduction in CA-125 levels from baseline. |
Measure: | Prostate specific antigen (PSA) response |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | PSA response is defined as at least a 50% reduction in PSA levels from baseline |
Measure: | Circulating Tumor Cells (CTC) count conversion for mCRPC patients |
Time Frame: | Day 1 Cycles 1-4 |
Safety Issue: | |
Description: | CTC conversion for mCRPC patients |
Measure: | Biomarker PD-L1 |
Time Frame: | Baseline |
Safety Issue: | |
Description: | PD-L1 expression level in baseline tumor tissue. |
Measure: | Presence of defects in a panel of key oncogenes |
Time Frame: | Baseline. |
Safety Issue: | |
Description: | Presence of defects in a panel of key oncogenes. |
Measure: | Plasma concentrations Ctrough talazoparib |
Time Frame: | Day 1, Day 15 Cycle 3 |
Safety Issue: | |
Description: | Pharmacokinetic parameter for talazoparib. |
Measure: | Plasma concentrations post-dose talazoparib |
Time Frame: | Day 1, Day 15 Cycle 3 |
Safety Issue: | |
Description: | Pharmacokinetic parameter for talazoparib. |
Measure: | Serum concentrations Ctrough avelumab |
Time Frame: | Day 1 Cycles 1, 3, 6, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameter for avelumab. |
Measure: | Serum concentrations Cmax avelumab |
Time Frame: | Day 1 Cycles 1, 3, 6, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameter for avelumab. |
Measure: | Anti-drug antibody (ADA) levels of avelumab |
Time Frame: | Day 1 Cycles 1, 3, 6, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Immunogenicity assessment of avelumab. |
Measure: | Neurtralizing antibodies (Nab) levels against avelumab |
Time Frame: | Day 1 Cycles 1, 3, 6, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Immunogenicity assessment of avelumab. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Pfizer |
Trial Keywords
Last Updated
April 5, 2021